Paraproteinemic neuropathies (PNs) encompass a heterogenous group of neurological disorders, which may not be clinically distinguishable from chronic inflammatory demyelinating neuropathy (CIDP). They are by definition associated with monoclonal gammopathy or plasma cell dyscrasia. The non-malignant forms have also been termed CIDP with monoclonal gammopathy of undetermined significance (MGUS-CIDP). 1 In spite of some experimental evidence, 2 a causative role of the paraprotein for the neuropathy has not yet been proven beyond doubt, and the exact pathophysiology in all these disorders has not yet been uncovered. 3 Only in a defined subset of patients does a monoclonal IgM kappa paraprotein react specifically with myelin-associated glycoprotein (MAG), and this is likely to be of pathogenic significance. 4 Standard treatment options include i.v. Igs, plasmapheresis or immunosuppressive treatment (for example, corticosteroids, azathioprine or CY) and-rarely-immunoselective treatment using monoclonal antibodies (anti-CD20, anti-TNF-alpha and anti-CD52). 5 The response to treatment is variable, but most patients can be stabilized or even improved. 5 Nevertheless, a group of patients remain refractory to these treatment modalities, including some of those with anti-MAGassociated neuropathy. 5 For these cases intensive immunosuppression followed by auto-SCT could be an alternative therapy concept. However, until now only two case reports have been published describing successful ASCT after highdose melphalan (HD-Mel) followed by amelioration of neurological symptoms. 6, 7 Here we report our experience on four patients with severe treatment-refractory acquired PN treated with HD-Mel and ASCT.
All patients were classified as having PNs of different subtypes according to the standard diagnostic criteria. 1 Patient characteristics including pretreatment efforts are listed in Table 1a . All patients provided informed consent for treatment and reporting of their data. CY and melphalan dosing was determined by protocol and depended on the patient's age, general condition and cardiac function. Patients received G-CSF s.c. once daily over 4 to 5 days before stem cell collection. The melphalan dose was divided over 2 consecutive days, with stem cell infusion 48 h after the last dose of melphalan.
Case 1
A 58-year-old man had a 2-year history of mainly distal paresthesias and hypesthesia before marked disease progression with loss of walking ability in spite of continued immunosuppressive treatment with corticosteroids and CY. Sural nerve biopsy showed a mixed axonal and demyelinating inflammatory neuropathy 8 with marked fiber loss. In November 2005, the patient was treated with HD-Mel and ASCT without serious problems and with subsequent improvement. In April 2006 a second course of HD-Mel with ASCT was performed. In the posttransplant period, the patient regained walking ability. Some mild sensorimotor deficits remained, mainly of the lower limbs.
Case 2
A 54-year-old man in a poor general condition with a 5-year history of a relapsing progressive demyelinating polyneuropathy was treated with HD-Mel with ASCT leading to significant improvement within a few weeks. Nine months later, the patient was able to resume his former job without continuous medication and recovered completely after 27 months post-transplantation.
Case 3
A 38-year-old woman suffered from a progressive painful tetraparesis that started in 2005. Sural nerve biopsy showed a moderate patchy axonal neuropathy with marked edema and perivascular inflammation in both the endo-and epineurium. Seven months later, when unable to walk, the patient received HD-Mel with ASCT. Owing to the slower recovery of megakaryopoiesis, a second donation of stem cells was performed. At 3 months post transplantation the patient regained the ability to stand, and at 26 months post transplantation the patient experienced an almost complete clinical remission.
Case 4
This 55-year-old male patient presented with a 9-year history of severely disabling progressive sensorimotor impairment. He received HD-Mel with ASCT and 2 months later, the patient was able to walk unaided again while sensory impairment and tremor intensity improved significantly.
The treatment response to HD-Mel therapy with ASCT is shown in Table 1b.
All the above patients suffered from severe disabling neuropathies associated with MGUS and failed to respond to various immunomodulatory or immunosuppressive treatments. Remarkably, pretreatment in two of the four patients even included immunoselective B-cell-depleting therapy with anti-CD20 monoclonal antibodies (Rituximab). All patients showed sustained clinical and electrophysiological improvement after ASCT. We suggest that the efficient reduction of plasma cell clones producing either pathogenic paraproteins (monoclonal Ig fraction) or other putatively pathogenic polyclonal auto-reactive antibodies provides a possible mechanism of action of HD-Mel with ASCT in this context. This is an attractive hypothesis even in view of the fact that two of the four patients had failed previous B-celldirected treatment with anti-CD20 monoclonal Ab because Rituximab does not inhibit or kill plasma cells and long-lived plasma cell clones. This is also in line with the short-term response to plasmapheresis in some patients. In two patients (nos. 1 and 2) immunofixation testing still showed paraproteins after ASCT despite excellent remission, arguing against an all-or-none causal role of the paraproteins (monoclonal antibodies) or any other putative autoantibodies in the circulation. Rather, multiple mechanisms may act in 
